Literature DB >> 3722509

Oral acyclovir for the prevention of herpes-associated erythema multiforme.

M A Lemak, M Duvic, S F Bean.   

Abstract

Herpes simplex virus is the single most common precipitator of erythema multiforme. Typically, erythema multiforme lesions appear 10 to 14 days after a recurrent herpes simplex virus infection and attacks can be disabling when they occur at frequent intervals. Prior to the introduction of acyclovir (Zovirax), there was no effective therapy to prevent herpes-associated erythema multiforme. Four patients were treated with a maintenance dose of acyclovir for periods ranging from 10 to 26 months; there were no significant side effects from the drug and only one recurrence of erythema multiforme. Oral acyclovir may become the treatment of choice for herpes-associated erythema multiforme.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3722509     DOI: 10.1016/s0190-9622(86)70141-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  7 in total

Review 1.  Pharmacological management of recurrent oral mucosal ulceration.

Authors:  J A Burgess; B D Johnson; E Sommers
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 2.  Use of steroids for erythema multiforme in children.

Authors:  Alfred K Yeung; Ran D Goldman
Journal:  Can Fam Physician       Date:  2005-11       Impact factor: 3.275

3.  Erythema multiforme-oral variant: case report and review of literature.

Authors:  Parvinderjit S Kohli; Jasbir Kaur
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-04-05

Review 4.  The role of oral acyclovir in the management of genital herpes simplex.

Authors:  S L Sacks
Journal:  CMAJ       Date:  1987-04-01       Impact factor: 8.262

Review 5.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

Review 6.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

Review 7.  Current Perspectives on Erythema Multiforme.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.